HIV-positive Patients

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers taking efavirenz had significantly faster nicotine metabolism (higher NMR) than those not taking efavirenz in a multiple regression model, with efavirenz alone accounting for 5% u

Effect: decline; b = 0.221, p = .010

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)

HIV-positive smokers had a higher mean NMR than previously reported in the general population of smokers, suggesting a greater proportion of fast nicotine metabolizers among PLWH.

Effect: decline; Mean NMR 0.47 (HIV+ sample) vs 0.34-0.39 (general population reference)